Marina Fridlib

776 total citations
6 papers, 550 citations indexed

About

Marina Fridlib is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marina Fridlib has authored 6 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cancer Research, 4 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marina Fridlib's work include Cancer, Lipids, and Metabolism (5 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Metabolomics and Mass Spectrometry Studies (2 papers). Marina Fridlib is often cited by papers focused on Cancer, Lipids, and Metabolism (5 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Metabolomics and Mass Spectrometry Studies (2 papers). Marina Fridlib collaborates with scholars based in United States. Marina Fridlib's co-authors include Richard Ventura, Julie Lai, George Kemble, Kasia Mordec, Timothy S. Heuer, Douglas Buckley, Joanna Waszczuk, Zhaoti Wang, Mohammed Inayathullah and Roham T. Zamanian and has published in prestigious journals such as Cancer Research, Science Translational Medicine and Molecular Cancer Therapeutics.

In The Last Decade

Marina Fridlib

6 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marina Fridlib United States 4 309 294 214 59 52 6 550
Junyu Huo China 14 161 0.5× 233 0.8× 208 1.0× 87 1.5× 57 1.1× 47 476
Bingjun Lu China 7 261 0.8× 322 1.1× 71 0.3× 69 1.2× 48 0.9× 12 479
Zhaoliang Lu China 12 211 0.7× 320 1.1× 149 0.7× 60 1.0× 77 1.5× 20 502
Jesús Méndez‐González Spain 9 194 0.6× 361 1.2× 117 0.5× 94 1.6× 44 0.8× 11 601
Qin Tan China 6 239 0.8× 306 1.0× 250 1.2× 29 0.5× 70 1.3× 13 498
Lingming Kong China 11 196 0.6× 293 1.0× 147 0.7× 91 1.5× 67 1.3× 19 481
Katherine A. Cottrill United States 8 242 0.8× 289 1.0× 268 1.3× 16 0.3× 8 0.2× 8 491
Ming Ma China 13 140 0.5× 289 1.0× 123 0.6× 117 2.0× 34 0.7× 56 490
Zhong Cheng China 13 192 0.6× 221 0.8× 98 0.5× 149 2.5× 42 0.8× 35 583

Countries citing papers authored by Marina Fridlib

Since Specialization
Citations

This map shows the geographic impact of Marina Fridlib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Fridlib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Fridlib more than expected).

Fields of papers citing papers by Marina Fridlib

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Fridlib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Fridlib. The network helps show where Marina Fridlib may publish in the future.

Co-authorship network of co-authors of Marina Fridlib

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Fridlib. A scholar is included among the top collaborators of Marina Fridlib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Fridlib. Marina Fridlib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
2.
O’Farrell, Marie, Katharine Grimmer, R. Webster Crowley, et al.. (2016). Abstract LB-214: FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study. Cancer Research. 76(14_Supplement). LB–214. 8 indexed citations
3.
4.
O’Farrell, Marie, R. Webster Crowley, Timothy S. Heuer, et al.. (2015). Abstract B13: Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients. Molecular Cancer Therapeutics. 14(12_Supplement_2). B13–B13. 1 indexed citations
5.
Heuer, Timothy S., Richard Ventura, Kasia Mordec, et al.. (2015). Abstract 4446: Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis. Cancer Research. 75(15_Supplement). 4446–4446. 2 indexed citations
6.
Tian, Wen, Xinguo Jiang, Rasa Tamošiūnienė, et al.. (2013). Blocking Macrophage Leukotriene B 4 Prevents Endothelial Injury and Reverses Pulmonary Hypertension. Science Translational Medicine. 5(200). 200ra117–200ra117. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junyu Huo Breakdown of academic impact, for papers by Bingjun Lu Breakdown of academic impact, for papers by Zhaoliang Lu Breakdown of academic impact, for papers by Jesús Méndez‐González Breakdown of academic impact, for papers by Qin Tan Breakdown of academic impact, for papers by Lingming Kong Breakdown of academic impact, for papers by Katherine A. Cottrill Breakdown of academic impact, for papers by Ming Ma Breakdown of academic impact, for papers by Zhong Cheng
Rankless by CCL
2026